| |
Multiple Cycles
of Chemotherapy
Clinical trials should
be designed to measure both nausea and vomiting over multiple
cycles of chemotherapy, yet this analysis of multiple cycles of
chemotherapy is complicated due to the dependence of each cycle
on previous cycles. In most trials, significant drop-out must
be accounted for between cycles. In addition, there may be overlap
between acute and delayed emesis from one cycle to another. Potential
overlap also exists between the delayed side effects of one cycle
and the anticipatory side effects of the next. Trial designs need
to account for these factors, and when reporting results, the
number of patients who drop out at each cycle for each arm should
be specified and the reasons for drop-out should be summarized.
|